In the European Union, Vimpat® (lacosamide) (film-coated tablets, syrup and solution for infusion) is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
Vimpat® solution for infusion may be used when oral administration is temporarily not feasible
Prescribing information Europe
In the US, Vimpat® (lacosamide) CV is indicated
- for the treatment of partial-onset seizures in patients 1 month of age and older
- as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older.
In the U.S., Vimpat® is available as oral tablets, oral solution and injection.
For availability of Vimpat® in other countries, please consult our local websites.